Edwards Lifesciences (NYSE: EW) files Form 144 to sell 26,000 shares
Rhea-AI Filing Summary
Edwards Lifesciences reported a Form 144 covering the proposed sale of 26,000 shares of Common Stock on 03/11/2026. The filing lists Employee Stock Option Exercise - Broker Payment for Cashless Exercise as the transaction method and identifies Charles Schwab & Co. as the broker.
Positive
- None.
Negative
- None.
Insights
Routine exercise-and-cashless disposition recorded by broker.
The Form 144 shows an employee stock option exercise where the broker handled a cashless payment and listed 26,000 shares to be sold on 03/11/2026. This pattern commonly reflects option vesting liquidity rather than open-market timing.
Timing and proceeds details are not in the excerpt; subsequent filings or trade reports would state execution outcomes and cash flows.
Form 144 documents a proposed resale under SEC resale notice requirements.
The filing lists the broker (Charles Schwab & Co.) and the transaction method verbatim: Broker Payment for Cashless Exercise. The entry on 03/11/2026 is a notice of intent to sell and not a confirmation of completed trades.
Cash‑flow recipients and net proceeds are not disclosed in the excerpt; enforcement- or reporting-related conditions are not shown.